Eli Lilly’s GLP-1 drugs are rocketing its stock, with 56% Q1 growth—but at 40x earnings, is it overvalued? The company’s eyeing approval for retatrutide next year, a next-gen obesity drug slashing weight by 20% and tackling heart disease and sleep apnea. Analysts forecast $4B annual revenue by 2030. Despite a 11% dip from its peak, this healthcare powerhouse may be undervalued as the GLP-1 market explodes.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
